Results Further Support The Benefits Of TYSABRI For Multiple Sclerosis Patients

Links shared publicly online about this topic.

1,750
total visits

Results Further Support The Benefits Of TYSABRI For Multiple Sclerosis Patients

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) have announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multi

View full resource at medicalnewstoday.com

Tags: Multiple Sclerosis, Tysabri, Biogen Idec, Elan Corp.

Most Recently Shared on September 14, 2009 at 11:48 am By:

Lisa Emrich

MedNewsToday: Results Further Support The Benefits Of TYSABRI For Multiple Sclerosis Patients: Biog.. http://bit.ly/jkuoc

3 years ago...

Retweet

Favorite

Also Shared By:

psychiatryrounds

Results Further Support The Benefits Of TYSABRI For Multiple Sclerosis Patients | Psydir News

news.psydir.com — “Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) have announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking TYSABRI (natalizumab) experienced an improvement in both their physical function and psychological well-being. Findings from the study, which was performed in conjunct...” View full resource at news.psydir.com